All In Biotech

NDA 019452 · Hill Dermac

Derma-Smoothe/Fs

Fluocinolone Acetonide · Topical, Otic · Corticosteroid

Last checked: Nov 20, 2026Latest source record: Aug 30, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1988

Feb 3, 1988

Approved uses

7

Original approval plus efficacy supplements

Registered trials

63

20 Phase 3, 7 recruiting

FAERS reports

2,062

880 serious, 48 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 27, 2026.

Derma-Smoothe/FS ® Scalp Oil is a corticosteroid indicated for the treatment of psoriasis of the scalp in adults. ( 1 ) DERMA-SMOOTHE/FS ® Scalp Oil is indicated for the treatment of psoriasis of the scalp in adults.

Mechanism: Corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action in psoriasis of the scalp is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • DERMA-SMOOTHE/FS · FLUOCINOLONE ACETONIDE 0.01% · OIL, TOPICAL · Prescription · TE AT
  • DERMA-SMOOTHE/FS · FLUOCINOLONE ACETONIDE 0.01% · OIL, TOPICAL · Prescription · TE AT
  • DERMOTIC · FLUOCINOLONE ACETONIDE 0.01% · OIL/DROPS, OTIC · Prescription · TE AT

Clinical trials

Interventional ClinicalTrials.gov studies with "Fluocinolone Acetonide" as an intervention, any sponsor and status, largest first.

All 63 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective209
  • pruritus205
  • rash165
  • diarrhoea129
  • psoriasis125
  • headache113
  • off label use113
  • fatigue107
  • pain105
  • dermatitis atopic93
  • nausea93
  • dry skin80

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20048
200515
200610
200712
200818
200931
201020
201156
201257
201325
201437
201564
201687
201782
201889
2019125
2020132
2021131
2022175
2023223
2024201
2025248
2026216

Recalls

4 FDA enforcement reports for this application.

  • May 21, 2021 · Class II · Terminated

    Presence of Foreign Substance: Potential for broken glass within the glass pipette of the dropper.

  • Jan 31, 2014 · Class III · Terminated

    Subpotent Drug: The active ingredient, fluocinolone acetonide, was found to be subpotent during the firm's routine testing.

  • Jan 31, 2014 · Class III · Terminated

    Subpotent Drug: The active ingredient, fluocinolone acetonide, was found to be subpotent during the firm's routine testing.

  • Jan 31, 2014 · Class III · Terminated

    Subpotent Drug: The active ingredient, fluocinolone acetonide, was found to be subpotent during the firm's routine testing.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Derma-Smoothe-FS (Fluocinolone Acetonide)

2024 spending

$6K

Beneficiaries

96

148 claims

Per beneficiary

$68

$0.31 per unit

View as table
YearSpending
2020$13,725
2021$12,564
2022$11,580
2023$11,896
2024$6,482

Part D: Derma-Smoothe-FS (Fluocinolone/Shower Cap)

2024 spending

$13K

Beneficiaries

243

339 claims

Per beneficiary

$52

$0.29 per unit

View as table
YearSpending
2020$26,871
2021$20,781
2022$19,664
2023$16,563
2024$12,526

Part D: Dermotic (Fluocinolone Acetonide Oil)

2024 spending

$36K

Beneficiaries

1,043

1,316 claims

Per beneficiary

$34

$1.35 per unit

View as table
YearSpending
2020$28,891
2021$29,530
2022$29,383
2023$32,855
2024$35,968

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 139 on PubMed

Sponsor: Hill Dermac · Also marketed as Dermotic

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.